AG Brown announced that his Antitrust Division has reached a settlement with Mylan Inc. (Mylan), the company that sells the EpiPen®, resolving concerns about anticompetitive conduct involving the cost, marketing, and availability of EpiPen products. 

“For too long, Mylan has cornered the market on this lifesaving medication and driven up costs for Maryland families who have had no choice but to pay. Today’s settlement goes a long way toward holding Mylan accountable for putting profit over the people who depend on this drug to protect their health and keep their loved ones safe.” – AG Brown